Optimal Strategies for Managing Adverse Events with GPRC5D Bispecifics in Multiple Myeloma : Episode 1
Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
A panel of experts on multiple myeloma discuss long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.
Now Viewing
EP: 1.Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
EP: 2.Adverse Event Management with BCMA Therapy
EP: 3.GPRC5D Therapy: Unique Challenges in Adverse Event Management
EP: 4.Overview of Long-term Follow-up from MonumenTAL-1
EP: 5.Overview of Other GPRC5D Therapy Clinical Trials
EP: 6.Administration and Dosing Management
EP: 7.Clinical Perspective on AE Tolerance
EP: 8.Clinical Experience in Managing AEs in GPRC5D Therapy
EP: 9.Management and Supportive Care for CRS and ICANS in GPRC5D Therapy
EP: 10.Insights on REMS Programs and Strategies for Effective Patient Care
EP: 11.Clinical Scenario: AE Management in a Patient with R/R MM on GPRC5D Therapy
EP: 12.Adverse Event Management Strategies in GPRC5D Therapy
EP: 13.Clinical Scenario: AE Management for Bispecific Therapy in R/R MM
Video content above is prompted by the following:
- Discuss the long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.
Recent Videos
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
